Advancing Medication Therapy Management Quality Measurement: A report from the PQA Quality Innovation and Research Initiative for Medication Therapy Management

Advancing Medication Therapy Management Quality Measurement: A report from the PQA Quality Innovation and Research Initiative for Medication Therapy Management

The Pharmacy Quality Alliance (PQA) issued an eight-point call to action for improving the quality and measurement of medication therapy management (MTM) services. The call was developed with extensive stakeholder input as part of a national, multi-phase initiative that PQA launched in 2023 to identify a pathway for new quality measures. It is the focus of this report, Advancing Medication Therapy Management Quality Measurement.

The call to action’s eight elements are:

• Investigate optimal MTM eligibility and targeting criteria for achieving program goals.
• Enhance collaboration between prescribers, MTM providers, and plan sponsors to better address patient goals of care and implement appropriate medication changes.
• Optimize patient and prescriber awareness of Part D MTM services and the benefits patients may receive.
• Amplify the patient voice to improve the patient-centeredness of MTM programs.
• Strengthen requirements for the use of standardized health information technology for documentation of MTM services.
• Increase consistent use of the PQA Medication Therapy Problem Categories Framework through stakeholder education.
• Develop new performance measures for MTM quality.
• Prioritize research to optimize the Part D MTM program and services.

The elements are not in priority order and require partnerships and coordinated efforts from a multitude of stakeholders across the industry. Their development was informed by an environmental scan, an in-person convening event, public comment period and follow-up webinar.

This MTM initiative is led by the PQA Quality Innovation and Research Center (QuIRC), a strategic initiative to accelerate progress in medication use quality and focus on clinical outcomes and provider contributions to care. The first phase of this initiative was funded in part by Novo Nordisk and Outcomes. PQA general funds, which include dues from PQA’s diverse, multi-stakeholder membership, also supported this work.